Solvay S.A.: Solvay second quarter 2026 results
Solvay reported Q2 2026 results. Underlying net sales were €1,031 million, down 7.4% organically, and underlying EBITDA was €187 million (18.1% margin), down 19.5% organically, citing weak soda ash pricing and Middle East disruption. Underlying net profit from continuing operations was €64 million. Full-year 2026 guidance was confirmed: EBITDA €770–€850 million and free cash flow at least €200 million. Solvay approved €15–20 million rare-earth capacity investments at La Rochelle.
How this was made
The 30-second read
Why it matters
The company confirms 2026 outlook, explicitly tying the recovery to a Q3 restart in Saudi Arabia and quantifying transformation expenses and currency impacts. It also updates rare earth capacity expansion plans at La Rochelle with additional €15-20m investments and future dysprosium/terbium industrial-scale separation.
Market read
Traders can update expectations for 2H earnings and cash flow based on the confirmed EBITDA and FCF ranges, the quantified Q2 weakness, and the operational restart catalyst in Q3.
What to watch
Free cash flow was weak in Q2 (-€115m) and H1 FCF is only €15m, so investors may scrutinize whether the €200m+ full-year FCF floor is achievable if restart timing or working-capital swings disappoint.
Background
Solvay’s Q2 performance is framed by soda ash pricing weakness and a Middle East conflict-related temporary shutdown of its Peroxides plant since mid-March.
Market effects
Signals continued softness in soda ash pricing and demonstrates how geopolitical disruptions can directly affect chemical production schedules and earnings cadence.
Middle East conflict is cited as impacting operations via a Peroxides plant shutdown, implying regional volatility risk for chemical supply chains.
Rare earth separation expansion at La Rochelle and dysprosium/terbium industrial-scale separation plans reinforce Europe’s push to diversify critical rare earth processing capacity.
Counterpoint
Guidance confirmation may not fully offset structural margin pressure, since Q2 EBITDA decline is partly driven by ongoing pricing weakness and transformation expense drag.
Key entities
- companySolvay S.A.
Chemical company reporting Q2 2026 results and confirming full-year 2026 guidance, including a planned Q3 Peroxides restart and rare earth capacity expansion.
- assetPeroxides plant (Saudi Arabia)
Temporary shutdown since mid-March due to Middle East conflict; restart expected in Q3 2026.
- facilityLa Rochelle rare earth separation facility
Rare earth separation plant outside China; Solvay approves €15-20m additional investments to extend separation capacities.
- counterpartyViridis
Named in a Letter of Intent to secure rare earth material supply from Brazil to Solvay’s La Rochelle plant.
